Cord Blood Transplantation for Patients With Cancer

• Status: Terminated
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Antilymphocyte Serum; Busulfan; Fludarabine; Fludarabine phosphate; Melphalan; Vidarabine

Criteria

Inclusion Criteria:

• Relapsed or refractory acute leukemia (myeloid or lymphoid)

• Acute leukemia in first remission at high-risk for recurrence

• Chronic myelogenous leukemia in accelerated phase or blast-crisis

• Chronic myelogenous leukemia in chronic phase

• Recurrent or refractory malignant lymphoma or Hodgkin lymphoma

• Chronic lymphocytic leukemia, relapsed or with poor prognostic features

• Multiple myeloma

• Myelodysplastic syndrome

• Chronic myeloproliferative disease

• Hemoglobinopathies

• Aplastic anemia

Exclusion Criteria:

• Zubrod performance status > 2

• Life expectancy is severely limited by concomitant illness

• Patients with severely decreased LVEF or impaired pulmonary function tests

• Estimated Creatinine Clearance <50 ml/min

• Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal

• Evidence of chronic active hepatitis or cirrhosis

• HIV-positive

• Patient is pregnant

• Patient or guardian not able to sign informed consent